Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials SAN FRANCISCO & NEW YORK & MELBOURNE, Australia--(BUSINESS WIRE) ...
NEW YORK--(BUSINESS WIRE)--Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ ...
These are exciting times at the intersection of artificial intelligence (AI) and neuroscience. The trend in brain-computer interfaces (BCIs) is toward flexible and less invasive devices that can ...
Synchron Inc.'s recent $2 million raise for its Stentrode brain-computer interface platform comes at a pivotal time for the technology. Advances in BCI development, ongoing clinical trials and growing ...
New York-based Synchron, a brain-computer interface (BCI) company, has raised $200 million in Series D funding, bringing its total raise to $345 million. Double Point Ventures led the round, with ...
A new protocol will allow users implanted with Synchron’s brain-computer interface (BCI) device to control iPhone, iPad and Apple Vision Pro directly with their thoughts without the need for physical ...
When a new technology shows promise, performance-wise and commercially, innovation does not stop. To the contrary, it gathers pace. New medical devices typically emerge from competing groups of ...
Apple is collaborating with brain-computer interface company Synchron to develop technology that lets users control devices using neural signals. “This marks a defining moment for human-device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results